Andere Sprachen Cynata Therapeutics Limited

Aktien

A1W8VE

AU000000CYP7

CYP

Markt geschlossen - Australian S.E. Andere Börsenplätze 08:10:11 03.05.2024			% 5 Tage	% 1. Jan.
0.24 ^AUD	+2.13%		+14.29%	+92.00%

08.04.	Cynata Therapeutics Limited schließt Patientenrekrutierung in der klinischen Studie zu CYP-006TK bei diabetischen Fußgeschwüren ab	CI
08.04.	Cynata Therapeutics schließt Patientenrekrutierung in Wundverband-Produktstudie für diabetische Fußgeschwüre ab	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical Trial	08.04.
Cynata Therapeutics Concludes Patient Enrolment in Diabetic Foot Ulcer Wound Dressing Product Trial	08.04.
Cynata Therapeutics Receives EU Approval for CYP-001 Phase 2 Trial	20.03.
Cynata Therapeutics Doses First Patient in Phase Two Trial of Cellular Therapy; Shares Rise 5%	05.03.
Cynata Therapeutics Limited Announces Updates on Phase 2 Clinical Trial of CYP-001	05.03.
Cynata Therapeutics Names Chief Business Officer; Shares Plunge 14%	29.02.
Cynata Therapeutics Limited Announces Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial	26.02.
Cynata Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	23.02.
Cynata Therapeutics Expects Initial Results in Diabetic Foot Ulcer Topical Wound Dressing Trial in Q1 2024	28.12.
Cynata Therapeutics Completes Recruitment for Phase Three Osteoarthritis Trial	13.12.
Cynata Therapeutics Secures Approval in Turkey for Phase 2 Trial of HR-aGvHD; Shares Jump 9%	07.12.
Cynata Therapeutics Receives AU$2.3 Million R&D Tax Rebate	14.11.
Acute Respiratory Distress Syndrome Pipeline \| Clinical Trials and Key Companies	08.11.
Cynata Therapeutics Secures Clearance to Advance Phase Three Knee Pain Trial	06.11.
Cynata Therapeutics Limited Announces Resignation of David Atkins as Director	08.10.23
Cynata Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	28.08.23
Cynata Therapeutics Opens Enrollment for Phase Two Cell Therapy Trial	10.08.23
Cynata Therapeutics Taps COO for CEO/Managing Director Role; Shares Down 4%	30.06.23
Cynata Therapeutics Limited Announces Management Appointments	30.06.23
Cynata Therapeutics Limited Announces Chief Executive Officer Changes	30.06.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cynata Therapeutics Limited

Aktien

A1W8VE

AU000000CYP7

CYP

Andere Sprachen

Filter